Pavel Trakhtman

Prof. Dr. Pavel Trakhtman

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
ZKZaira Kharaeva
Zaira Kharaeva
ASAlbina Shokarova
Albina Shokarova
ZSZalina Shomakhova
Zalina Shomakhova
GIGalina Ibragimova
Galina Ibragimova
PTPavel Trakhtman
Pavel Trakhtman
Liudmila G. KorkinaLiudmila G. Korkina
Liudmila G. Korkina
Food supplements based on fermented Carica papaya and Morinda citrifolia, known for their immune modulating, redox balancing, and anti-inflammatory effects, were added to conventional treatment protocols prescribed to patients recovering after severe and moderate COVID-19 disease in order to alleviate long-lasting post-COVID symptoms. A randomized single-center placebo-controlled clinical laboratory study was designed and performed (total number of participants 188, with delta variant of virus 157, with omicron 31). Clinical statuses were assessed using computer tomography, electrocardiography, a questionnaire, and physical endurance. Plasma cytokines (IL-6, IL-8, IL-17A, and INF-gamma), nitrate/nitrite ratio, antioxidant activity (AOA), and polymorphonuclear leukocyte (PMN) ATP levels were determined before and 20 days following the addition of 28 g of fermented supplements twice per day. The capacity of PMN to phagocyte and the oral-nasal-pharyngeal microbiota were assessed. Clinical symptoms, IL-6, IL-8, and nitric oxide metabolites diminished significantly compared to the placebo group and their background expression. The PMN capacity to phagocyte, AOA, and ATP content remarkably increased. The oral-nasal-pharyngeal microbiota were unchanged. On these grounds, we suggest that fermented tropical fruits could efficiently diminish post-COVID clinical symptoms through several immune-modulating, redox balancing, and pro-energy mechanisms.

19 February 2019 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
PTPavel Trakhtman
Pavel Trakhtman
IKIrina Kumukova
Irina Kumukova
NSNikolay Starostin
Nikolay Starostin
DBDaria Borsakova
Daria Borsakova
DBDmitry Balashov
Dmitry Balashov
ARAlexander Rumiantcev
Alexander Rumiantcev

18 March 2016 in Transfusion
Verified
Journal Article
Closed access
PDF file
PTPavel Trakhtman
Pavel Trakhtman
OKOksana Karpova
Oksana Karpova
DBDmitri Balashov
Dmitri Balashov
EKElena Kurnikova
Elena Kurnikova
VPValentina Pirumova
Valentina Pirumova
ARAlexander Rumiantsev
Alexander Rumiantsev

7 June 2004 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
AMA A Maschan
A A Maschan
PTPavel Trakhtman
Pavel Trakhtman
DBD N Balashov
D N Balashov
ISI P Shipicina
I P Shipicina
ESE V Skorobogatova
E V Skorobogatova
ARA G Rumiantsev
A G Rumiantsev
Allogeneic hematopoietic stem cell transplantation (SCT) from unaffected donors remains the only modality for the correction of hematological abnormalities in Fanconi anemia (FA) patients. We performed four HLA-matched related donor SCT using a novel irradiation and cyclophosphamide-free conditioning regimen. The protocol included fludarabine 150 mg/m2, busulfan 4 mg/kg, and antithymocyte globulin 90 mg/kg. Graft-versus-host disease (GVHD) prophylaxis was cyclosporin A, MTX, and daclizumab. The engraftment and occurrence of full stable donor hemopoiesis was rapid in all cases with minimal short-term toxic complications. There were no infections or febrile episodes during the inpatient phase. Three patients developed acute GVHD grade I–II involving gut and skin and one patient progressed to extensive chronic GVHD. The preparative conditioning regimen is safe and associated with low organ toxicity and effective immunosupression for the stable engraftment in FA patients undergoing SCT with matched related donors.

11 March 2020 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
GGGennadiy Galstyan
Gennadiy Galstyan
TGT. V. Gaponova
T. V. Gaponova
EZE. B. Zhiburt
E. B. Zhiburt
EBE. N. Balashova
E. N. Balashova
ABA. L. Berkovskiy
A. L. Berkovskiy
VSV. G. Savchenko
V. G. Savchenko
Background. Cryoprecipitate is made from fresh-frozen plasma (FFP) and contains fibrinogen, factor VIII, factor XIII, von Willebrand factor, fibronectin and fibrinogen.Aim. To provide information on the composition and methods of production, storage, transportation and clinical use of cryoprecipitate.General findings. Cyoprecipitate is manufactured by slowly thawing FFP at 1–6°C. This precipitates out cryoproteins: factor VIII, von Willebrand factor, factor XIII, fibronectin and fibrinogen. After centrifugation, the cryoproteins are resuspended in a reduced volume of plasma. Cryoprecipitate is stored at temperatures not exceeding –25° С for 36 months. Indications for cryoprecipitate transfusion are hemophilia A, von Willebrand disease, factor XIII deficiency, congenital afibrinogenemia and hypofibrinogenemia, acquired hypofibrinogenemia. These indications can occur in obstetrics, neonatology, cardiac surgery, neurosurgery, hematology, orthopaedics, and general surgery during liver transplantation and disseminated intravascular coagulation.

30 June 2020 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
ALAlexandra Laberko
Alexandra Laberko
ESElvira Sultanova
Elvira Sultanova
EGElena Gutovskaya
Elena Gutovskaya
SRSvetlana Radygina
Svetlana Radygina
EDElena Deripapa
Elena Deripapa
DBDmitry Balashov
Dmitry Balashov